title: Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity.
abstract: Mitoxantrone is similar to Adriblastin in its mechanism of action and antitumor activity. Objective remissions were obtained in 20-30% pretreated patients and in 23-44% of untreated patients by single-drug treatment of patients suffering from metastatic breast cancer. The objective response rates to Mitoxantrone in combination with CTX, 5-FU, MTX, VCR, MMC. Prednimustine or Vindesine were 16-46% in treatment and 38-89% in primary treatment. Randomized studies comparing Mitoxantrone with Adriblastin in single-drug and combination treatment did not show any significant differences in efficacy. However, Mitoxantrone was significantly less toxic. Remission rates of between 24 and 54% were achieved by single-drug treatment in pretreated patients suffering from non-Hodgkin lymphoma. Mitoxantrone appears to be active in ovarian cancer, lung cancer and hepatocellular carcinoma.
authors.affiliation: Central Institute of Cancer Research, Academy of Sciences, Berlin, G.D.R.
authors.forename: H
authors.initials: H
authors.lastname: Lenk
authors.forename: U
authors.initials: U
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Tanneberger
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D008942:Mitoxantrone